,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'destiny-breast03', 'breast']
great presentation from with updated safety data from destiny-breast03. no new safety signals emerged. most events g1/g2. 8% ild pneumonitis leading to d/c of t-dxd. higher n/v, fatigue and alopecia in t-dxd arm in initial treatment cycles. #bcsm #asco22 
Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ??